344 related articles for article (PubMed ID: 22643066)
21. Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance.
Krumbach R; Schüler J; Hofmann M; Giesemann T; Fiebig HH; Beckers T
Eur J Cancer; 2011 May; 47(8):1231-43. PubMed ID: 21273060
[TBL] [Abstract][Full Text] [Related]
22. EGFR codon 497 polymorphism - implications for receptor sensitivity to inhibitors in HNSCC cell lines.
Krohn V; Wiegand S; Werner JA; Mandic R
Anticancer Res; 2011 Jan; 31(1):59-65. PubMed ID: 21273581
[TBL] [Abstract][Full Text] [Related]
23. Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells.
Ansell A; Jedlinski A; Johansson AC; Roberg K
J Oral Pathol Med; 2016 Jan; 45(1):9-16. PubMed ID: 25677871
[TBL] [Abstract][Full Text] [Related]
24. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib.
Agulnik M; da Cunha Santos G; Hedley D; Nicklee T; Dos Reis PP; Ho J; Pond GR; Chen H; Chen S; Shyr Y; Winquist E; Soulieres D; Chen EX; Squire JA; Marrano P; Kamel-Reid S; Dancey J; Siu LL; Tsao MS
J Clin Oncol; 2007 Jun; 25(16):2184-90. PubMed ID: 17538163
[TBL] [Abstract][Full Text] [Related]
25. Imaging of epidermal growth factor receptor expression in head and neck cancer with SPECT/CT and 111In-labeled cetuximab-F(ab')2.
van Dijk LK; Hoeben BA; Kaanders JH; Franssen GM; Boerman OC; Bussink J
J Nucl Med; 2013 Dec; 54(12):2118-24. PubMed ID: 24136932
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy.
Hitt R; Ciruelos E; Amador ML; Benito A; Sanchez JJ; Ballestin C; Cortes-Funes H
Eur J Cancer; 2005 Feb; 41(3):453-60. PubMed ID: 15691646
[TBL] [Abstract][Full Text] [Related]
27. The efficacy of combined treatment with cetuximab (erbitux) and radiation therapy in patients with head and neck cancer.
Koukourakis G; Kouloulias V; Koukourakis M; Kouvaris J; Zacharias G; Gouliamos A
J BUON; 2009; 14(1):19-25. PubMed ID: 19373942
[TBL] [Abstract][Full Text] [Related]
28. Epidermal growth factor receptor biology in head and neck cancer.
Kalyankrishna S; Grandis JR
J Clin Oncol; 2006 Jun; 24(17):2666-72. PubMed ID: 16763281
[TBL] [Abstract][Full Text] [Related]
29. Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines.
Kalish LH; Kwong RA; Cole IE; Gallagher RM; Sutherland RL; Musgrove EA
Clin Cancer Res; 2004 Nov; 10(22):7764-74. PubMed ID: 15570011
[TBL] [Abstract][Full Text] [Related]
30. Significance of interleukin-6 signaling in the resistance of pharyngeal cancer to irradiation and the epidermal growth factor receptor inhibitor.
Chen CC; Chen WC; Lu CH; Wang WH; Lin PY; Lee KD; Chen MF
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1214-24. PubMed ID: 20206020
[TBL] [Abstract][Full Text] [Related]
31. Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines.
Hoffmann T; Hafner D; Ballo H; Haas I; Bier H
Anticancer Res; 1997; 17(6D):4419-25. PubMed ID: 9494544
[TBL] [Abstract][Full Text] [Related]
32. Targeting EGFR-positive cancer cells with cetuximab-ZZ-PE38: Results of in vitro and in vivo studies.
Barnea I; Ben-Yosef R; Karaush V; Benhar I; Vexler A
Head Neck; 2013 Aug; 35(8):1171-7. PubMed ID: 22965815
[TBL] [Abstract][Full Text] [Related]
33. Epidermal growth factor receptor protein detection in head and neck cancer patients: a many-faceted picture.
Thariat J; Etienne-Grimaldi MC; Grall D; Bensadoun RJ; Cayre A; Penault-Llorca F; Veracini L; Francoual M; Formento JL; Dassonville O; De Raucourt D; Geoffrois L; Giraud P; Racadot S; Morinière S; Milano G; Van Obberghen-Schilling E
Clin Cancer Res; 2012 Mar; 18(5):1313-22. PubMed ID: 22228639
[TBL] [Abstract][Full Text] [Related]
34. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.
Johnson FM; Saigal B; Donato NJ
J Cell Physiol; 2005 Nov; 205(2):218-27. PubMed ID: 15887238
[TBL] [Abstract][Full Text] [Related]
35. Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas.
Smilek P; Neuwirthova J; Jarkovsky J; Dusek L; Rottenberg J; Kostrica R; Srovnal J; Hajduch M; Drabek J; Klozar J
Neoplasma; 2012; 59(5):508-15. PubMed ID: 22668015
[TBL] [Abstract][Full Text] [Related]
36. Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells.
O-charoenrat P; Modjtahedi H; Rhys-Evans P; Court WJ; Box GM; Eccles SA
Cancer Res; 2000 Feb; 60(4):1121-8. PubMed ID: 10706134
[TBL] [Abstract][Full Text] [Related]
37. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
Le Tourneau C; Siu LL
Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
[TBL] [Abstract][Full Text] [Related]
38. Relationship between epidermal growth factor receptor status, p16(INK4A), and outcome in head and neck squamous cell carcinoma.
Young RJ; Rischin D; Fisher R; McArthur GA; Fox SB; Peters LJ; Corry J; Lim A; Waldeck K; Solomon B
Cancer Epidemiol Biomarkers Prev; 2011 Jun; 20(6):1230-7. PubMed ID: 21467228
[TBL] [Abstract][Full Text] [Related]
39. Involvement of EGFR in the response of squamous cell carcinoma of the head and neck cell lines to gefitinib.
Taguchi T; Tsukuda M; Imagawa-Ishiguro Y; Kato Y; Sano D
Oncol Rep; 2008 Jan; 19(1):65-71. PubMed ID: 18097577
[TBL] [Abstract][Full Text] [Related]
40. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.
Yonesaka K; Zejnullahu K; Lindeman N; Homes AJ; Jackman DM; Zhao F; Rogers AM; Johnson BE; Jänne PA
Clin Cancer Res; 2008 Nov; 14(21):6963-73. PubMed ID: 18980991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
